{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:42:08Z","timestamp":1788964928365,"version":"build-2803163510"},"reference-count":9,"publisher":"Bioscientifica","content-domain":{"domain":["edm.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,5,17]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>Medullary thyroid cancer (MTC) is a rare neuroendocrine tumour that originates from the parafollicular cells of the thyroid gland. The most common presentation of MTC is with a single nodule; however, by the time of diagnosis, most have spread to the surrounding cervical lymph nodes. Cushing\u2019s syndrome is a rare complication of MTC and is due to ectopic adrenocorticotrophic hormone (ACTH) secretion by tumour cells. Cushing\u2019s syndrome presents a challenging diagnostic and management issue in patients with MTC. Tyrosine kinase inhibitors (TKI) previously used for the management of metastatic MTC have become an important therapeutic option for the management of ectopic ACTH in metastatic MTC. The article describes three cases of ectopic ACTH secretion in MTC and addresses the significant diagnostic and management challenges related to Cushing\u2019s syndrome in metastatic MTC.<\/jats:p>\n                  <jats:sec>\n                    <jats:title>Learning points:<\/jats:title>\n                    <jats:list list-type=\"bullet\">\n                      <jats:list-item>\n                        <jats:p>Medullary thyroid cancer (MTC) is a rare neuroendocrine tumour.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>Cushing\u2019s syndrome is a rare complication of MTC that has a significant impact on patients\u2019 morbidity and mortality.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>Tyrosine kinase inhibitors (TKI) provide an important therapeutic option for the management of ectopic ACTH in metastatic MTC.<\/jats:p>\n                      <\/jats:list-item>\n                    <\/jats:list>\n                  <\/jats:sec>","DOI":"10.1530\/edm-16-0110","type":"journal-article","created":{"date-parts":[[2017,5,17]],"date-time":"2017-05-17T09:23:26Z","timestamp":1495013006000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-2","source":"Crossref","is-referenced-by-count":7,"title":["ACTH-secreting medullary thyroid cancer: a case series"],"prefix":"10.1530","volume":"2017","author":[{"given":"Ayanthi A","family":"Wijewardene","sequence":"first","affiliation":[{"name":"1Departments of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah J","family":"Glastras","sequence":"additional","affiliation":[{"name":"2Departments of Endocrinology, Diabetes & Metabolism, Royal North Shore Hospital, Sydney Australia"},{"name":"3Kolling Institute of Medical Research"},{"name":"4Sydney Medical School, University of Sydney, Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana L","family":"Learoyd","sequence":"additional","affiliation":[{"name":"2Departments of Endocrinology, Diabetes & Metabolism, Royal North Shore Hospital, Sydney Australia"},{"name":"4Sydney Medical School, University of Sydney, Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce G","family":"Robinson","sequence":"additional","affiliation":[{"name":"2Departments of Endocrinology, Diabetes & Metabolism, Royal North Shore Hospital, Sydney Australia"},{"name":"4Sydney Medical School, University of Sydney, Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venessa H M","family":"Tsang","sequence":"additional","affiliation":[{"name":"2Departments of Endocrinology, Diabetes & Metabolism, Royal North Shore Hospital, Sydney Australia"},{"name":"4Sydney Medical School, University of Sydney, Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"key20170519132927109_bib1","doi-asserted-by":"crossref","first-page":"242","DOI":"10.5694\/j.1326-5377.2004.tb05894.x","article-title":"Thyroid nodules and thyroid cancer","volume":"6180","author":"Mackenzie","year":"2004","journal-title":"Medical Journal of Australia"},{"key":"key20170519132927109_bib2","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1089\/thy.2014.0335","article-title":"Revised american thyroid association guidelines for the management of medullary thyroid carcinoma","volume":"25","author":"Wells","year":"2015","journal-title":"Thyroid"},{"key":"key20170519132927109_bib3","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/dc.20502","article-title":"Role of FNA cytology and immunochemistry in the diagnosis and management of medullary thyroid carcinoma: report of six cases and review of the literature","volume":"35","author":"Bhanot","year":"2007","journal-title":"Diagnostic Cytopathology"},{"key":"key20170519132927109_bib4","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1365-2265.2008.03229.x","article-title":"Long-term prognosis of medullary thyroid carcinoma","volume":"69","author":"Rendl","year":"2008","journal-title":"Clinical Endocrinology"},{"key":"key20170519132927109_bib5","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1089\/thy.2005.15.618","article-title":"Ectopic adrenocorticotropic hormone-syndrome in medullary carcinoma of the thyroid: a retrospective analysis and review of the literature","volume":"15","author":"Barbosa","year":"2005","journal-title":"Thyroid"},{"key":"key20170519132927109_bib6","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1210\/jc.2013-4340","article-title":"Vandetanib successfully controls medullary thyroid cancer-related Cushing syndrome in an adolescent patient","volume":"99","author":"Nella","year":"2014","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"key20170519132927109_bib7","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"key20170519132927109_bib8","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMc1301428","article-title":"Reversal of Cushing\u2019s syndrome by vandetanib in medullary thyroid carcinoma","volume":"369","author":"Baudry","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"key20170519132927109_bib9","doi-asserted-by":"crossref","first-page":"e30353","DOI":"10.1371\/journal.pone.0030353","article-title":"Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysis","volume":"7","author":"Zang","year":"2012","journal-title":"PLoS ONE"}],"container-title":["Endocrinology, Diabetes &amp; Metabolism Case Reports"],"original-title":[],"link":[{"URL":"https:\/\/edm.bioscientifica.com\/view\/journals\/edm\/2017\/1\/EDM16-0110.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/edm.bioscientifica.com\/downloadpdf\/journals\/edm\/2017\/1\/EDM16-0110.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:46:26Z","timestamp":1784555186000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/edm\/article\/3309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,17]]},"references-count":9,"URL":"https:\/\/doi.org\/10.1530\/edm-16-0110","relation":{},"ISSN":["2052-0573"],"issn-type":[{"value":"2052-0573","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,17]]}}}